Modality
Multispecific
MOA
PD-L1i
Target
TROP-2
Pathway
Tau
MigraineThymomaHuntington's
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
~Oct 2022
→ ~Jan 2024
NDA/BLA
Apr 2024
→ May 2031
NDA/BLACurrent
NCT05669274
273 pts·Migraine
2024-04→2031-05·Recruiting
273 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-265.2y awayPh3 Readout· Migraine
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-05-26 · 5.2y away
Migraine
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05669274 | NDA/BLA | Migraine | Recruiting | 273 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |